Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting minimal residual disease: a path to cure?
Marlise R. Luskin, Mark A. Murakami, Scott R. Manalis, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 4, pp. 255-263
Open Access | Times Cited: 135

Showing 76-100 of 135 citing articles:

Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Camille Léonce, Pierre Saintigny, Sandra Ortiz-Cuarán
Molecular Cancer Research (2021) Vol. 20, Iss. 1, pp. 11-29
Open Access | Times Cited: 11
Targeted Therapy in Early Stage Non-small Cell Lung Cancer
Si‐Yang Liu, Si‐Yang Maggie Liu, Wen‐Zhao Zhong, et al.
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 9, pp. 1169-1184
Closed Access | Times Cited: 8
Extracellular Vesicle-Based Communication May Contribute to the Co-Evolution of Cancer Stem Cells and Cancer-Associated Fibroblasts in Anti-Cancer Therapy
Gábor Valcz, Edit I. Buzás, Anna Sebestyén, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2324-2324
Open Access | Times Cited: 11
Clinical application of circulating tumor DNA in breast cancer
Jeffrey Chan, James Chung Hang Chow, Connie Hoi Man Ho, et al.
Journal of Cancer Research and Clinical Oncology (2021) Vol. 147, Iss. 5, pp. 1431-1442
Closed Access | Times Cited: 10
Circulating Tumor DNA in Pediatric Cancer
Louise Doculara, Toby N. Trahair, Narges Bayat, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 7
Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancer
Kaixuan Shi, Haijiao Lu, Zhenfeng Zhang, et al.
Cell Death and Differentiation (2022) Vol. 30, Iss. 1, pp. 195-207
Open Access | Times Cited: 7
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells
Matthew Holmes, Gina B. Scott, Samuel Heaton, et al.
Molecular Therapy — Oncolytics (2023) Vol. 29, pp. 17-29
Open Access | Times Cited: 4
Long-term outcome of centrally located hepatocellular carcinoma treated by neoadjuvant radiotherapy and radical resection: a propensity score matched study
Changcheng Tao, Fan Wu, Yue Liu, et al.
Annals of Medicine and Surgery (2023) Vol. 86, Iss. 1, pp. 78-84
Open Access | Times Cited: 4
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma
Jian Cui, Tengteng Yu, Rui Lv, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Cancer Stem Cells: Current Challenges and Future Perspectives
Muhammad Vaseem Shaikh, Stefan Custers, Alisha Anand, et al.
Methods in molecular biology (2024), pp. 1-18
Closed Access | Times Cited: 1
Novel synthetic ecteinascidins exhibit potent anti-melanoma activity by suppressing super-enhancer-driven oncogenic transcription
Max Cigrang, Julian Obid, Maguelone Nogaret, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Mutation and cell state compatibility is required and targetable in Ph+acute lymphoblastic leukemia minimal residual disease
Peter Winter, Michelle L. Ramseier, Andrew W. Navia, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Minimal residual disease monitoring via ctDNA: a case report of Lynch syndrome with synchronous colorectal cancer and review of literature
Cody Eslinger, Christina Wu, Daniel H. Ahn
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 3, pp. 1341-1347
Open Access | Times Cited: 1
Purinergic Ca2+ Signaling as a Novel Mechanism of Drug Tolerance in BRAF-Mutant Melanoma
Philip E. Stauffer, Jordon Brinkley, David A. Jacobson, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2426-2426
Open Access | Times Cited: 1
Liquid biopsy for monitoring minimal residual disease in colorectal cancer: A promising approach with clinical implications
Z. Wang, Junge Bai, Dedi Jiang, et al.
Clinical Surgical Oncology (2024) Vol. 3, Iss. 3, pp. 100056-100056
Open Access | Times Cited: 1
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers
Pedro C. Barata, Kevin Zarrabi, Axel Bex, et al.
European Urology (2024)
Closed Access | Times Cited: 1
What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non–Small-Cell Lung Cancer
Si‐Yang Liu, Jia‐Tao Zhang, Yi‐Long Wu
Journal of Clinical Oncology (2021) Vol. 40, Iss. 3, pp. 217-220
Open Access | Times Cited: 9
The prospects of tumor chemosensitivity testing at the single-cell level
Chuan Yang, Caibo Yang, Yosef Yarden, et al.
Drug Resistance Updates (2020) Vol. 54, pp. 100741-100741
Open Access | Times Cited: 9
Liquid Biopsies for Molecular Biology-Based Radiotherapy
Erik Blomain, Everett J. Moding
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11267-11267
Open Access | Times Cited: 8
EMP1+ tumor cells drive metastatic relapse
Oscar E. Villarreal, Scott Kopetz
Cell Research (2023) Vol. 33, Iss. 5, pp. 337-338
Open Access | Times Cited: 3
Clinical Benefits of Neoadjuvant Radiotherapy on the Postoperative Recurrence of Centrally Located Hepatocellular Carcinoma: A Real-World Evidence Based on Phase II Clinical Trial
Changcheng Tao, Fan Wu, Hongwei Wang, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 753-764
Open Access | Times Cited: 3
Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection
Hind Hassan, Sakti Chakrabarti, Tyler Zemla, et al.
European Journal of Surgical Oncology (2023) Vol. 49, Iss. 11, pp. 106994-106994
Closed Access | Times Cited: 3
A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanoma
Oskar Marín-Béjar, Aljosja Rogiers, Michael Dewaele, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 7
Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
Carlos Bravo‐Pérez, María Sola, Raúl Teruel‐Montoya, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4332-4332
Open Access | Times Cited: 7
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?
Nicola Gökbuget
Hematology (2021) Vol. 2021, Iss. 1, pp. 718-725
Open Access | Times Cited: 7

Scroll to top